Pluri Inc. 2023 Investor Presentation - Regenerative Medicine & Cell Technology

Pluri is an Israel-based regenerative medicine company with a proprietary 3D cell expansion technology platform. The company has early-to-late stage clinical development assets, collaborations in food-tech and biologics sectors, and 140 patents globally. As of March 2023, Pluri maintains approximately $45 million in cash and deposits, trading on Nasdaq (PLUR) and TASE.